Third Annual “Merck Millipore Pharma Forum” to Address Latest Developments in Pharmaceutical Raw Materials Industry

April 10, 2012, Darmstadt, Germany — Merck Millipore, the Life Science division of Merck KGaA* of Darmstadt, Germany, announced today that it will host the third annual Merck Millipore Pharma Forum on June 12, 2012, at the company’s headquarters in Darmstadt, Germany. The event will bring together industry experts and manufacturers of pharmaceutical raw materials to discuss the state of the market and challenges facing the industry.

Presentations and discussions will explore the recent launch of the new excipients certification program EXCiPACT™, Qualified Person’s responsibility for GMP compliant raw materials and liability issues surrounding deficient pharmaceutical raw materials. Results from a recent Merck Millipore study focusing on leachables and extractables will also be examined.

“We are very excited to host the third annual Merck Millipore Pharma Forum,” said Dr. Matthias Bucerius, Head of Pharma Raw Materials. “This event will allow manufacturing and pharmaceutical professionals to learn about the latest regulatory and quality assurance issues facing the pharmaceutical raw materials market today. Attendees will have a rare opportunity to engage and interact with industry experts on the topics that matter most in our industry.”

Merck Millipore Pharma Forum 2012 speakers will include:

• Dr. Iain Moore, IPEC Europe and Croda Europe
• Dr. Bernd Renger, European QP Association
• Dr. Najib Sehat, Merck Millipore, Darmstadt
• Dr. Martin Wesch, Wesch & Buchenroth Lawyers
• Dr. Christian Wolf, Central Analytical Services, Merck KGaA, Darmstadt

For a complete event program, schedule of presentations or additional details about the Merck Millipore Pharma Forum 2012 please visit www.merck4pharma.com/forum.

About Merck Millipore
Merck Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, Merck Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2010 revenues of EUR 1.7 million. Merck Millipore operates as EMD Millipore in the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany